Science
Paolo Tarantino: U.S. Real-World Outcomes After First-Line Ribociclib in HR+/HER2− Metastatic Breast Cancer

Paolo Tarantino: U.S. Real-World Outcomes After First-Line Ribociclib in HR+/HER2− Metastatic Breast Cancer

Paolo Tarantino, Research Fellow Dana-Farber Cancer Institute and Harvard Medical Schoolpost, shared a post on X:

“Just out in ESMO Open – real-world post-progression outcomes after 1L AI+ribociclib in Flatiron (n=5649). The use of first line ribociclib (vs AI alone) was associated with longer PFS2 and chemo-free survival, including among patients aged ≥65 years.”

 

Title: Real-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States of America

Authors: L. Hart, H.S. Rugo, P. Sharma, S. Sammons, V.K. Gadi, P. Mavros, M. Kaur, N. Boualam, C. Keane, G. Sopher, P. Pathak, P. Tarantino

Read the Full Article.

Paolo Tarantino: U.S. Real-World Outcomes After First-Line Ribociclib in HR+/HER2− Metastatic Breast Cancer

Other articles featuring Paolo Tarantino on OncoDaily.

Breast Cancer C. Keane cancer ESMO Open G. Sopher H S Rugo L. Hart M. Kaur N. Boualam OncoDaily Oncology P. Mavros P. Pathak P. Sharma P. Tarantino Paolo Tarantino S. Sammons V.K. Gadi